Companies with marketing authorisation for medicines would, for the first time, not only have the right, but would now be obliged to make available certain information, such as labelling and the package leaflet of the medicine.
Ettevõtetel, kellel on ravimite müügiluba, on esmakordselt nii õigus kui ka kohustus teha kättesaadavaks kindel teave ravimi kohta, nagu märgistamine ja ravimi infoleht.